• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    IGM Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

    5/29/25 4:05:25 PM ET
    $IGMS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IGMS alert in real time by email
    8-K
    0001496323false00014963232025-05-232025-05-23

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 23, 2025

     

     

    IGM Biosciences, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-39045

    77-0349194

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    325 E. Middlefield Road

     

    Mountain View, California

     

    94043

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (650) 965-7873

    Not Applicable

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.01 per share

     

    IGMS

     

    The Nasdaq Global Select Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     


     

    Item 1.01 Entry into a Material Definitive Agreement

    The information set forth in Item 1.02 of this Current Report on Form 8-K is incorporated by reference into this Item 1.01.

    Item 1.02 Termination of a Material Definitive Agreement

    On May 23, 2025, IGM Biosciences, Inc. (the “Company”) entered into a Second Amendment to Lease (the “Agreement”) with Real Property Investments, LLC, a Colorado limited liability company (“Landlord”) with respect to the Company’s lease (the “Lease”) of its headquarters at 325 East Middlefield Road, Mountain View, CA (the “Premises”). The Agreement provides that the Lease will terminate on May 31, 2025 (the “Lease Termination Date”).

    As consideration for Landlord’s entry into the Agreement and acceleration of the expiration date of the Lease, the Company has agreed to: (a) pay to Landlord a lease termination payment of $14.2 million, $0.2 million of which will be credited from the security deposit paid to Landlord by the Company and (b) convey ownership to Landlord of certain items of personal property, furniture and fixtures located within the Premises. The Company will have no further rent obligations to Landlord pursuant to the Lease or Agreement following the Lease Termination Date.

    The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

    Item 9.01 Financial Statements and Exhibits

    (d) Exhibits

     

    Item No.

     

    Description

     

     

    10.1

     

    Second Amendment to Lease, dated May 23, 2025*

     

     

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

    * Schedules and exhibits omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish supplementally a copy of any omitted schedule or exhibit to the Securities and Exchange Commission upon request. The Company may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedules or exhibits so furnished.

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

     

    IGM BIOSCIENCES, INC.

     

     

     

     

    Date:

    May 29, 2025

    By:

    /s/ Misbah Tahir

     

     

     

    Misbah Tahir

     

     

     

    Chief Financial Officer

     

     


    Get the next $IGMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IGMS

    DatePrice TargetRatingAnalyst
    1/10/2025$21.00 → $2.00Outperform → Market Perform
    BMO Capital Markets
    1/10/2025$12.00 → $2.00Equal-Weight → Underweight
    Morgan Stanley
    1/10/2025$27.00 → $2.50Buy → Hold
    Stifel
    1/10/2025$20.00 → $1.50Outperform → Sector Perform
    RBC Capital Mkts
    1/10/2025Buy → Neutral
    Guggenheim
    12/6/2024$21.00Outperform
    BMO Capital Markets
    10/1/2024$12.00 → $9.00Neutral → Underweight
    JP Morgan
    10/1/2024$24.00 → $12.00Buy → Hold
    Truist
    More analyst ratings

    $IGMS
    SEC Filings

    See more
    • IGM Biosciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - IGM Biosciences, Inc. (0001496323) (Filer)

      6/11/25 5:07:57 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - IGM Biosciences, Inc. (0001496323) (Filer)

      5/29/25 4:05:25 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by IGM Biosciences Inc.

      10-Q - IGM Biosciences, Inc. (0001496323) (Filer)

      5/13/25 4:05:32 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IGMS
    Leadership Updates

    Live Leadership Updates

    See more
    • Medivir Appoints Jens Lindberg as Chief Executive Officer

      STOCKHOLM, Oct. 25, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Board of Directors has appointed Jens Lindberg as CEO of the company. Jens Lindberg has extensive experience from the pharmaceutical industry and the field of Oncology. He joins from Sedana Medical where he has been VP Commercial and acting CEO. Jens Lindberg started his career in the pharmaceutical industry in 1995 as a sales representative for Astra, later AstraZeneca. During a 25-year span at AstraZeneca, Jens held numerous roles in Commercial & Investor Relations, spanning local & global responsibilities as well as development of phase 2/3 programs to maximise the commercial value for o

      10/25/21 2:45:00 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences Announces Leadership Appointments and Formation of IGM Infectious Diseases and IGM Autoimmunity and Inflammation Business Units

      – John Shiver, Ph.D., and Tong-Ming Fu, M.D., Ph.D., Appointed as Chief Strategy Officer and Chief Scientific Officer, Respectively, of IGM Infectious Diseases – – Mary Beth Harler, M.D., Appointed as President of IGM Autoimmunity and Inflammation – MOUNTAIN VIEW, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced the formation of two business units: IGM Infectious Diseases and IGM Autoimmunity and Inflammation. These new business units will utilize and build upon IGM's platform technology to create and develop novel IgM and IgA antibodies to ad

      10/11/21 4:05:00 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Medivir appoints Malene Jensen as VP Clinical Development

      STOCKHOLM, July 1, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Malene Jensen as Vice President Clinical Development. She will assume her role as VP Clinical Development after the summer, at the latest October 1, 2021. Malene Jensen will also join the company's executive team. Malene Jensen has held various leadership positions within Clinical Development in the pharmaceutical industry for the past 15 years, including at AstraZeneca, Affibody and most recently as Director Global Clinical Development at Sedana Medical. She holds a PhD in Clinical Neuroscience from Karolinska Institutet in Stockholm. "We are pleased to welcome Malene and her vast cl

      7/1/21 11:54:00 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IGMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Baker Bros. Advisors Lp bought $3,425,569 worth of shares (395,317 units at $8.67) (SEC Form 4)

      4 - IGM Biosciences, Inc. (0001496323) (Issuer)

      3/28/24 7:04:05 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Baker Bros. Advisors Lp bought $3,431,464 worth of shares (532,693 units at $6.44) (SEC Form 4)

      4 - IGM Biosciences, Inc. (0001496323) (Issuer)

      12/15/23 5:32:35 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IGMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs

      – Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December 31, 2024 – MOUNTAIN VIEW, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a biotechnology company committed to developing and delivering medicines to treat patients with autoimmune and inflammatory diseases, today announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 bispecific antibody T cell engager, for autoimmune diseases.    "Interim data

      1/9/25 1:00:00 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

      – Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for generalized myasthenia gravis by year-end 2024 – – Cash runway expected to fund operations into 2027 – MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended September 30, 2024 and provided an update on recent developments. "The third quarter was transformative for IGM, punct

      11/8/24 7:00:00 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences to Present at Three Upcoming Investor Conferences

      MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will present at three upcoming investor conferences: Guggenheim Healthcare Innovation Conference on Monday, November 11 at 11:30 a.m. EST in BostonStifel Healthcare Conference on Tuesday, November 19 at 12:40 p.m. EST in New YorkJefferies London Healthcare Conference on Thursday, November 21 at 8:00 a.m. GMT/ 3:00 a.m. EST in London A live webcast of the events will be available on the "Events and Presentations" page in the "Investors" section of the Company's website at http

      11/4/24 7:00:00 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IGMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • IGM Biosciences downgraded by BMO Capital Markets with a new price target

      BMO Capital Markets downgraded IGM Biosciences from Outperform to Market Perform and set a new price target of $2.00 from $21.00 previously

      1/10/25 8:15:47 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded IGM Biosciences from Equal-Weight to Underweight and set a new price target of $2.00 from $12.00 previously

      1/10/25 8:15:47 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences downgraded by Stifel with a new price target

      Stifel downgraded IGM Biosciences from Buy to Hold and set a new price target of $2.50 from $27.00 previously

      1/10/25 8:15:16 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IGMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRINCIPAL ACCOUNTING OFFICER Weber Steven sold $2,090 worth of shares (1,865 units at $1.12), decreasing direct ownership by 6% to 27,016 units (SEC Form 4)

      4 - IGM Biosciences, Inc. (0001496323) (Issuer)

      5/16/25 4:05:57 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lee Michael Stewart was granted 828 shares (SEC Form 4)

      4 - IGM Biosciences, Inc. (0001496323) (Issuer)

      4/2/25 9:01:06 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Redmile Group, Llc was granted 828 shares (SEC Form 4)

      4 - IGM Biosciences, Inc. (0001496323) (Issuer)

      4/2/25 9:00:16 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IGMS
    Financials

    Live finance-specific insights

    See more
    • IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

      – Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for generalized myasthenia gravis by year-end 2024 – – Cash runway expected to fund operations into 2027 – MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended September 30, 2024 and provided an update on recent developments. "The third quarter was transformative for IGM, punct

      11/8/24 7:00:00 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

      – Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus – – Mary Beth Harler, M.D., appointed as Chief Executive Officer and to Board of Directors – – Cash runway extended into 2027 – – Company to hold conference call and webcast today at 4:30 p.m. EDT – MOUNTAIN VIEW, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced a strategic pivot and pipeline transformation to accelerate and deepen its leadership in the development

      9/30/24 4:01:00 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate Update

      – Enrollment complete in aplitabart randomized colorectal cancer clinical trial; top-line PFS results expected by the end of 1Q25 – – Second dose cohort cleared in imvotamab rheumatoid arthritis clinical trial – – First dose cohort cleared in imvotamab systemic lupus erythematosus clinical trial – MOUNTAIN VIEW, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) --  IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced its financial results for the fiscal quarter ended June 30, 2024 and provided an update on recent developments. "We continue to make significant progress in the clinical

      8/14/24 7:00:00 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IGMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by IGM Biosciences Inc.

      SC 13G/A - IGM Biosciences, Inc. (0001496323) (Subject)

      11/14/24 1:22:39 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by IGM Biosciences Inc.

      SC 13G/A - IGM Biosciences, Inc. (0001496323) (Subject)

      11/12/24 10:32:10 AM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by IGM Biosciences Inc.

      SC 13G/A - IGM Biosciences, Inc. (0001496323) (Subject)

      8/2/24 6:41:27 PM ET
      $IGMS
      Biotechnology: Pharmaceutical Preparations
      Health Care